Please join us in thanking Peter Farina, Ph.D., for his 22 years of exceptional stewardship as a director and co-chair of BioCT’s board.
Throughout his unmatched tenure, Peter has served as a mentor, collaborator, and innovator deeply committed to the growth and success of BioCT, previously known as CURE, as well as to Connecticut’s life science industry. From the very early days, Peter took an active role in seeding the infrastructure which has developed to support the vitality and growth of the industry. He has been instrumental in building a constructive economic climate for the industry that has also positively impacted Connecticut’s well-being.
Peter has been a tireless advocate and steady voice for the patient community throughout his career and board tenure;, working with countless entrepreneurs and scientists to deliver innovative therapies and therapeutics to improve outcomes for both patients and their families.
“Peter joined the CURE board a year after the organization was founded. With Peter’s guidance, CURE evolved over the years to become BioCT, an important contributor to the growth and success of the greater life science industry. His leadership throughout the years has been invaluable. Thank you, Peter, for all your passion in support of BioCT and the industry,” said Dawn Hocevar, President & CEO of BioCT.
Stan Choy, Board Chair of BioCT, added, “I want to thank Peter for his 22 years serving Connecticut through his role on the board. His dedication to promoting the state’s life science and biotech industry has put us in a position of terrific strength. His presence on the board will be missed and we wish him the very best.”
Peter is currently an Executive in Residence at Canaan Partners. His accomplishments in drug R&D include the development and registration of treatments for HIV, COPD/emphysema, and diabetes. Previously, he was the Senior Vice President of Development for Boehringer Ingelheim Pharmaceuticals. Peter holds a Ph.D. in organic chemistry from SUNY Buffalo and completed postdoctoral work in bioorganic chemistry at Pennsylvania State University. He also received an honorary Ph.D. from the University of Connecticut.